87005
document
The individual responsiveness to growth hormone ( GH ) treatment in GH-deficient adults is dependent on the level of GH-binding protein , body mass index , age , and gender . The aim of the present trial was to study the individual responsiveness to GH treatment in terms of body composition and to search for possible predictors of the response in GH-deficient adults . Sixty-eight patients ( 44 men and 24 women ) with a mean age of 44.3 ( 1.2 ) yr and verified GH deficiency participated in a 2-phase treatment trial with an initial randomized , double blind , placebo-controlled , 6-month period , followed by an open treatment period , thereby ensuring all patients 12 months of GH treatment . Recombinant human GH was administered sc daily at bedtime , with a target dose of 12 micrograms/kg x day . GHBP was measured by ligand-mediated immunofunctional assay , and serum insulin-like growth factor I ( IGF-I ) was determined by RIA after acid-ethanol extraction , using a truncated IGF-I analog as the radioligand . Lean body mass ( LBM ) and body fat ( BF ) were determined by dual energy x-ray absorptiometry , and total body water ( TBW ) was determined by bioelectrical impedance . During the placebo control period , serum IGF-I , LBM , and TBW increased ( P < 0.001 ) , whereas BF decreased ( P < 0.001 ) and serum GHBP was unchanged in the group treated with GH compared with the patients treated with placebo . After 12 months of GH treatment , the individual changes in BF ranged from -12.5 to 4.3 kg and from -4.5 to 10.1 kg in LBM . Age ( P < 0.05 ) and baseline GHBP level ( P < 0.01 ) were inversely correlated with the increase in LBM . The GH-induced increment in IGF-I and TBW was greater in men than in women ( P < 0.01 ) , whereas the decreases in BF were similar in men and women . This trial demonstrates the variability in responsiveness to GH administration in GH-deficient adults . The best response to GH was obtained in younger patients with low GHBP levels . Furthermore , men responded better than women .
87006
Intervention_Pharmacological
growth hormone ( GH ) treatment
87007
Intervention_Pharmacological
GH treatment
87008
Intervention_Control
placebo-controlled
87009
Intervention_Pharmacological
Recombinant human GH
87010
Intervention_Pharmacological
GH
87011
Outcome_Physical
body mass index
87012
Outcome_Physical
Lean body mass ( LBM )
87013
Outcome_Physical
body fat ( BF )
87014
Outcome_Physical
serum IGF-I
87015
Outcome_Physical
LBM
87016
Outcome_Physical
TBW
87017
Outcome_Physical
BF
87018
Outcome_Physical
serum GHBP
87019
Outcome_Physical
BF
87020
Outcome_Physical
baseline GHBP level
87021
Outcome_Physical
GH-induced increment in IGF-I and TBW
87022
Outcome_Physical
BF
87023
Participant_Condition
GH-deficient
87024
Participant_Age
adults
87025
Participant_Sample-size
Sixty-eight
87026
Participant_Sample-size
44
87027
Participant_Sex
men
87028
Participant_Sample-size
24 women
87029
Participant_Age
mean age of 44.3 ( 1.2 ) yr
87030
Participant_Condition
verified GH deficiency